88568-95-0 Usage
Description
(+/-)-Benzyloxycarbonyl-alpha-phosphono-glycine trimethyl ester is a white crystalline powder that serves as a versatile starting material in organic synthesis. It is particularly useful in the preparation of (Z)-dehydroamino acids through the Wittig-Horner reaction with aldehydes. The resulting dehydroamino acids can be stereoselectively reduced to amino acids, making this compound an important intermediate in the synthesis of various biologically active molecules.
Uses
Used in Pharmaceutical Industry:
(+/-)-Benzyloxycarbonyl-alpha-phosphono-glycine trimethyl ester is used as a key intermediate in the synthesis of calcitonin gene-related peptide antagonists. These antagonists have potential therapeutic applications in treating various conditions, such as pain and inflammation.
Used in Amino Acid and Peptide Research:
(+/-)-BENZYLOXYCARBONYL-ALPHA-PHOSPHONOGLYCINE TRIMETHYL ESTER is also utilized in the synthesis of dehydroamino acid esters, which are essential for amino acid and peptide research. The ability to produce dehydroamino acids selectively allows for the development of new methods and techniques in the field of organic chemistry and biochemistry.
Used in Organic Synthesis:
(+/-)-Benzyloxycarbonyl-alpha-phosphono-glycine trimethyl ester serves as a valuable starting material for the synthesis of (Z)-dehydroamino acids through the Wittig-Horner reaction with aldehydes. This reaction is a widely used method for the preparation of various organic compounds, including those with potential applications in medicine, agriculture, and other industries.
Check Digit Verification of cas no
The CAS Registry Mumber 88568-95-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,8,5,6 and 8 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 88568-95:
(7*8)+(6*8)+(5*5)+(4*6)+(3*8)+(2*9)+(1*5)=200
200 % 10 = 0
So 88568-95-0 is a valid CAS Registry Number.
InChI:InChI=1/C13H18NO7P/c1-18-12(15)11(22(17,19-2)20-3)14-13(16)21-9-10-7-5-4-6-8-10/h4-8,11H,9H2,1-3H3,(H,14,16)/t11-/m1/s1
88568-95-0Relevant articles and documents
Preparation method of Wittig-Horner reagent
-
Paragraph 0030-0032; 0038-0040, (2021/07/31)
A preparation method of a Wittig-Horner reagent is disclosed. According to the preparation method of the Wittig-Horner reagent provided by the invention, a compound with a structure as shown in a formula (I) and a glyoxylic acid aqueous solution with a sp
SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS
-
, (2013/09/26)
The present invention relates to a series of substituted compounds having the general formula (I), including their ste reoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3. R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.
Scalable synthesis of the desoxy-biphenomycin B core
Berwe, Mathias,Joentgen, Winfried,Krueger, Jochen,Cancho-Grande, Yolanda,Lampe, Thomas,Michels, Martin,Paulsen, Holger,Raddatz, Siegfried,Weigand, Stefan
, p. 1348 - 1357 (2012/01/12)
We describe the evolution of a kilogram-scale synthesis of the protected cyclic tripeptide desoxy-biphenomycin B, based on an early discovery route. The retrosynthetic concept included a macrolactamization strategy to build the core ring system of biphenomycin B in combination with a double catalytic asymmetric hydrogenation protocol for the construction of the ansa-tripeptide precursor. Eventually, the kilogram process comprised a 16-step sequence with an overall yield for the longest linear sequence of 19.5%.
